Redefining
precision
medicine.
AI enabled data curation for drug development
Our mission is to advance the understanding of lung and heart disease.
We do this through our AI-powered data and imaging curation platform. It allows us to build products that accelerate clinical trials, identify new endpoints, and build synthetic control arms to assess the impact of treatments. By every metric (including drug development time, diagnostic cost and drug reimbursement spend), the opportunities for lung and heart disease are larger than all cancers combined.
Our AI-powered technology stack enables collaborative analysis for imaging, clinical data and biomarkers
Uncovering powerful insights from complex healthcare data
A connected view of disease
Purpose-built technology created by world-leading healthcare experts
Our current diseases of interest
Interstitial lung diseases
Interstitial lung diseases (ILDs) are a group of diseases which cause scarring and damage to the lung tissue itself. They can be difficult to diagnose and monitor and clinical trial development pathways can be complex.
They encompass over 200 individual diseases including Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis and Hypersensitivity Pneumonitis. Drug treatment can vary from steroids to immunosuppression to antifibrotics. Some patients may have associated pulmonary hypertension and others may need a lung transplant.
Pulmonary hypertension
Pulmonary Hypertension (PH) is an umbrella term for a group of conditions which cause an increased pressure in the heart/lung vascular circuit. This pressure increase can be caused by a range of diseases including autoimmune diseases, problems with the lungs or the heart itself, blood clots or can be of unknown cause. Monitoring it can be hard, needing invasive procedures to pass tubes into the blood vessels to directly measure the pressures. A new range of drugs to treat these diseases are being developed by many different biopharma companies.
Lung cancer
Lung cancer is one of the most common and fatal types of cancer. It can be associated with smoking, genetics or industrial exposures. The cancer can be primary, which starts in the lung, or secondary, which has spread to the lungs from other parts of the body. Treatments include surgery, radiotherapy, chemotherapy and targeted immunotherapy. Some of the newer medications can cause damage to the lung tissue surrounding the cancer as a side effect of the treatment.
Trusted by our partners to help them develop life changing drugs
Qureight is becoming a real powerhouse in understanding lung fibrosis and related pathological lung processes. Our collaboration helps us gain key insights regarding patient characteristics and drug effects on fibrosis and lung vasculature, and showing how Buloxibutid works in IPF
MD PhD, Chief Medical Officer, Vicore
"we've made it a priority to leverage cutting-edge technology"
Given the complex nature of PPF, we've made it a priority to leverage cutting-edge technology to measure treatment response in our ongoing MIST study. This collaboration with Qureight will allow us to measure changes in fibrosis volume more sensitively while also enabling us to quantify changes across multiple compartments of the lung.
MD, FCCP, CMO
